0.06
+0.0015(+2.70%)
Currency In USD
Address
399 Binney Street
Cambridge, MA 02139
United States of America
Phone
617 679 9600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
July 18, 2018
| Name | Title | Pay | Year Born |
| Ms. Dannielle Appelhans | Chief Executive Officer & Pres | 422,980 | 1983 |
| Dr. Laurence A. Turka M.D. | Chief Scientific Officer and Head of Research & Translational Medicine | 626,550 | 1958 |
| Mr. Jose I. Carmona M.B.A. | Principal Accounting Officer & Treasurer | 659,195 | 1972 |
| Mr. Craig R. Jalbert CIRA | President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director | 0 | 1962 |
| Ms. Marissa Hanify | Director of Corporate Communications | 0 | N/A |
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.